Articles |

Mesothelioma and Radical Multimodality Therapy: Who Benefits? FREE TO VIEW

David J. Sugarbaker; Michael T. Jaklitsch; Michael J. Liptay
Author and Funding Information

From the Division of Thoracic Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston

1995 by the American College of Chest Physicians

Chest. 1995;107(6_Supplement):345S-350S. doi:10.1378/chest.107.6_Supplement.345S
Text Size: A A A
Published online


The incidence of malignant pleural mesothelioma is increasing. Untreated, patients with this disease experience a rapid and horrendous clinical decline. Surgery plays a role in the diagnosis, staging, and treatment of this malignancy. Surgery, chemotherapy, and radiotherapy alone have been unable to achieve major improvements in survival for most patients. More recent phase II trials suggest that surgery, at one time a purely palliative approach, may have a potentially curative role when used in combination with chemotherapy and radiotherapy.




Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543